AChE/BChE/MAO-B-IN-1 is a reversible, non-time-dependent inhibitor of AChE, BChE and MAO-B that crosses the blood-brain barrier and exhibits inhibitory effects on hAChE, hBChE and hMAO-B with IC50s of 7.31, 0.56 and 26.1 μM, respectively. 1 had a neuroprotective effect and was not significantly cytotoxic.

MAO-B-IN-5 is a potent, selective and orally active MAO-B inhibitor with an IC 50 of 0.204 μM. MAO-B-IN-5 has the research potential in Parkinson's disease (PD) [1].

MAO-B-IN-9 is a monoamine oxidase B MAO-B inhibitor (IC50: 0.18 μM) that crosses the blood-brain barrier with potency, selectivity and time-dependence. MAO-B-IN-9 has neuroprotective effects against Aβ1-42-induced neuronal cell death, which may be related to the anti-aggregation effect of Aβ1-42.

MAO-B-IN-1 is a monoamine oxidase B inhibitor and can be used for the research of neurological diseases.

MAO-B-IN-19, a selective MAO-B inhibitor, exhibits neuroprotective and anti-inflammatory properties and demonstrates an IC50 value of 0.67 μM [1].

MAO-B-IN-26 (Compound IC9) serves as both a MAO-B and acetylcholinesterase inhibitor. It safeguards SH?SY5Y cells from Aβ-induced toxicity, including morphological alterations, reactive oxygen species (ROS) production, and membrane damage, while also preventing Aβ-triggered autophagy and apoptosis. As such, MAO-B-IN-26 holds potential as a neuroprotective agent in the context of Alzheimer’s disease [1].

MAO-B-IN-27 (Compound 12c), a monoamine oxidase B (MAO-B) inhibitor, exhibits a potent and selective inhibitory effect on hMAO-B, with an IC50 value of 8.9 nM, and is utilized in Parkinson's disease (PD) research [1].

AChE/BuChE/MAO-B-IN-2 (compound 4b) is a potent inhibitor of AChE, BuChE, and hu MAO-B, with respective IC50 values of 5.3 μM, 12.4 μM, and 1.9±0.08 μM, indicating good in vitro blood-brain barrier (BBB) permeability. It is effective in reducing excessive AChE and BuChE levels associated with Alzheimer's disease (AD) and holds potential for use in anti-Alzheimer's research [1].

MAO-B-IN-24 (compound 11h) is a selective, reversible, competitive inhibitor of MAO-B with an IC50 value of 1.60 μM. It also exhibits inhibitory effects on MAO-A with an IC50 of 22.42 μM. At a concentration of 10 μM, MAO-B-IN-24 reduces the activities of AChE and BChE to 54.58% and 88.43%, respectively [1].

MAO-IN-3 (Compound 5), a reversible and competitive monoamine oxidase (MAO) inhibitor with inhibition constants (K i) of 0.6 μM for MAO A and 0.2 μM for MAO B, effectively suppresses LN-229 glioblastoma cell proliferation, as denoted by an inhibitory concentration (IC50) of 0.8 μM. This compound holds potential application in cancer research [1].

Dual AChE-MAO B-IN-5, an indanone derivative, serves as an effective dual inhibitor for AChE and MAO-B, displaying IC50 values of 0.0224 μM for AChE, 0.0412 μM for MAO-B, and 0.1116 μM for MAO-A. Additionally, it exhibits antioxidant properties and inhibits β-amyloid plaque aggregation, making it suitable for Alzheimer’s disease (AD) research.

AChE/MAO-IN-1 is a potent inhibitor of human acetylcholinesterase (AChE), monoamine oxidase A (MAO-A), and monoamine oxidase B (MAO-B), demonstrating inhibitory concentrations (IC50) of 0.0248 μM, 0.0409 μM, and 0.1108 μM against AChE, MAO-A, and MAO-B, respectively.

MAO-B-IN-20 (Compound C14), a potent MAO-B inhibitor boasting an IC50 of 0.037 μM, demonstrates excellent metabolic stability and brain-blood barrier permeability. It holds potential for Parkinson's disease research [1].

Dual AChE-MAO B-IN-2 is a potent, dual inhibitor of AChE (IC50: 0.12 μM) and MAO B (IC50: 0.01 μM).Dual AChE-MAO B-IN-2 has potential for Alzheimer's disease studies.

Dual AChE-MAO B-IN-1 (compound 15) is a safe, metabolically stable neuroprotective agent.Dual AChE-MAO B-IN-1 is a potent, orally active CNS-permeable inhibitor of human AChE (IC50=550 nM) and MAO-B (IC50=8.2 nM), and has low in vitro activity against AChE and MAO-B with IC50 values of 550 nM, 8.2 nM respectively.

MAO-B-IN-11, also known as Compound 8c, is a highly potent inhibitor of monoamine oxidase B (MAO-B), with an IC50 value of 1.3 μM. Additionally, MAO-B-IN-11 exhibits neuroprotective properties [1].

MAO-B inhibitor 58 is an effective, selective, and reversible inhibitor of monoamine oxidase B.

MAO-B-IN-15 is a selective inhibitor of MAO-B that forms π-π interaction with Tyr 326 residue (IC 50 = 13.5 μM) which can be used in Parkinson’s disease research[1].

MAO-B-IN-18 is a potent, selective inhibitor of MAO B, demonstrating IC50 values of 52 nM for hMAO B and 14 μM for hMAO A. It exhibits cytoprotective effects against hydrogen peroxide-induced damage in neuroblastoma and astrocyte cultures [1].

MAO-B-IN-25 (compound 92) is a selective inhibitor of monoamine oxidase B (MAO-B), exhibiting inhibitory half-maximal inhibitory concentrations (IC50) of 240 nM for MAO-B and 0.5 nM for MAO-A [1].

MAO A/HDAC-IN-1 is an effective monoamine oxidase A (MAO A) and HDAC dual inhibitor, which can be used for glioma research.

AChE/BChE/MAO-B-IN-3, an indan-1-one derivative, serves as a potent inhibitor of human monoamine oxidase B (MAO-B) with an IC50 of 0.0359 μM, demonstrating significant inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50 values of 0.0473 μM and 0.0782 μM, respectively. Exhibiting notable antioxidant activity, AChE/BChE/MAO-B-IN-3 holds considerable promise for Alzheimer's disease (AD) research.

AChE/BChE/MAO-B-IN-4, an indan-1-one derivative, serves as a potent inhibitor for both monoamine oxidase B (MAO-B) and acetylcholinesterase/butyrylcholinesterase (AChE/BChE) enzymes. It exhibits a strong inhibitory effect on human MAO-B with an IC50 of 0.0393 μM, and demonstrates significant potency against human AChE and BChE enzymes with IC50 values of 0.0458 μM and 0.075 μM, respectively. Additionally, this compound displays notable antioxidant properties and the ability to prevent β-amyloid plaque aggregation, marking its potential utility in Alzheimer's disease (AD) research.

MAO-B-IN-16 is a selective inhibitor of monoamine oxidase B (MAO-B ) (IC 50 = 1.55 μM) that can be used in the central nervous disorders study, for example, parkinson's disease [1].

MAO-B-IN-17 is a selective and potent monoamine oxidase B (MAO-B) inhibitor (IC50: 5.08 μM) for the study of central nervous system disorders like Parkinson's.

MAO A/HSP90-IN-2 (compound 4-C), a dual inhibitor of HSP90 and MAO A, exhibits IC50 values of 0.016 μM for MAO A and 4.58 μM for HSP90. This compound not only enhances HSP70 expression but also diminishes HER2 and phospho-Akt levels, and downregulates IFN-γ-induced PD-L1 expression in GL26 cells. Demonstrating efficacy against Temozolomide-sensitive and -resistant GBM cells, colon cancer, leukemia, non-small cell lung cancer, and other malignancies, MAO A/HSP90-IN-2 may also impede tumor immune evasion [1].

MAO-B-IN-3 is a reversible, selective inhibitor of monoamine oxidase B (MAO-B) with an IC50 of 96 nM and demonstrates affinity for the 5-HT6 receptor with a Ki of 696 nM, making it suitable for Alzheimer's disease research [1].

MAO-B-IN-22 (compound 6h) represents a powerful MAO-B inhibitor, boasting an IC50 value of 0.014 μM, and exhibits high antioxidant activity alongside effective metal-chelating properties. It also demonstrates adequate BBB permeability and notable neuroprotective effects [1].

MAO-B-IN-4 (Compound 26) is a reversible monoamine oxidase B (MAO-B) inhibitor with potent in vitro activity, characterized by an IC50 value of 9 nM. This orally active compound exhibits favorable metabolic stability, a satisfactory safety profile, and effective brain permeability. Demonstrating antidepressant effects in rodent models, MAO-B-IN-4 is suitable for research into Alzheimer's disease [1].

MAO-B-IN-14 (Compound 9) is a potent and selective inhibitor of monoamine oxidase-B (MAO-B) with an IC 50 of 0.95 μM and a Ki of 0.55 μM for human MAO-B.

MAO-B-IN-30 is a selective and potent MAO-B inhibitor that crosses the blood-brain barrier with antiproliferative activity and inhibits both MAO-A and MAO-B.MAO-B-IN-30 reduces the levels of TNF-alpha, IL-6, and NF-kB in organisms, and can be used to study Parkinson's-type neurological disorders.

MAO-B-IN-13 (compound 12a) is a highly potent, reversible and blood-brain barrier (BBB) penetrant MAO-B inhibitor (IC50 = 10 nM). MAO-B-IN-13 shows neuroprotective and antioxidant activity which can be used in Parkinson’s disease research [1].

MAO-B-IN-23, also known as Compound 11f, is a reversible and competitive monoamine oxidase B (MAO-B) inhibitor with an IC50 value of 1.44 μM and a Ki of 0.51 μM [1].

5-HT6R/MAO-B modulator 1 is an antagonist of 5-HT6R at Gs signaling and an irreversible inhibitor of MAO-B that exhibits glial protective activity. 5-HT6R/MAO-B modulator 1 exhibits induction of scopolamine-induced memory deficits.

MAO-B-IN-10 (compound 4f) is a highly potent and selective inhibitor of MAO-B (monoamine oxidase-B). It effectively penetrates the blood-brain barrier and exhibits an IC50 of 5.3 μM. This compound demonstrates the ability to inhibit self-mediated Aβ (amyloid β) aggregation by 58.2% and disaggregate it by 43.3%. Thus, MAO-B-IN-10 holds promise for Alzheimer's disease research [1].

AChE/BChE/MAO-B-IN-2 is a potent inhibitor of the enzymes AChE, BChE, and MAO-B, with IC50 values of 48.2 nM, 83.9 nM, and 31.2 nM, respectively. It exhibits significant antioxidant activity and is applicable in Parkinson’s disease research.

AChE/MAO-B-IN-3 is a dual inhibitor targeting both acetylcholinesterase (AChE) and monoamine oxidase B (MAO-B), exhibiting inhibitory concentrations (IC50s) of 0.0257 μM and 0.0456 μM against human AChE and MAO-B, respectively. This compound holds potential for Alzheimer’s disease research.

HDAC1/MAO-B-IN-1 has the potential to be used in the Alzheimer’s disease research. HDAC1/MAO-B-IN-1 is a potent and selective inhibitor of HDAC1/MAO-B that can cross the blood-brain barrier. The IC50 values of HDAC1/MAO-B-IN-1 for HDAC1 and MAO-B are 21.4 nM and 99.0 nM, respectively [1].

MAO-B-IN-2 is a selective and competitive inhibitor of MAO-B and BChE with IC 50 values of 0.51 and 7.00 μM, respectively. MAO-B-IN-2 attenuates H2O2-induced cellular damage via good ROS scavenging property.

MAO A/HSP90-IN-1 (4-b) is a dual inhibitor of MAO A and HSP90, exhibiting IC50 values of 1.77 μM in glioblastoma (GBM) GL26 cells and 0.019 μM against HSP90α. This compound impairs the activities of MAO A, disrupts HSP90 binding, and downregulates both HER2 and phospho-Akt expressions, thereby inhibiting GBM growth. Additionally, it diminishes PD-L1 expression, thereby thwarting T cell activation and potential tumor immune evasion. MAO A/HSP90-IN-1 (4-b) is valuable for research into brain tumor-related diseases [1].

Dual AChE-MAO B-IN-3 (Compound C10) is a potent inhibitor of both AChE and MAO-B, exhibiting IC50 values of 0.58 μM and 0.41 μM, respectively. This dual-binding inhibitor targets the catalytic anionic site and peripheral anionic site of AChE, making it relevant for Alzheimer’s disease (AD) research [1].

MAO-B-IN-21 is an MAO-B inhibitor characterized by superior antioxidant and anti-Aβ aggregation activities. The compound additionally shows metal-ion chelating capabilities, mitigates neuroinflammation (NO, TNF-α), and demonstrates neuroprotective effects with notable BBB permeability. In an Aβ1-42 induced Alzheimer's disease mouse model, MAO-B-IN-21 markedly enhances memory and cognitive functions [1].

MAO-B-IN-7 is a potent and blood-brain barrier permeable MAO-B and AChE inhibitor. MAO-B-IN-7 exhibits IC50 s of 41 nM, 87 nM and 0.3 μM for human AChE, electric eel AChE and MAO-B, respectively. MAO-B-IN-7 effectively alleviates oxidative stress and neuroinflammatory damage.

MAO-B-IN-6 is a selective, potent, orally active MAO-B inhibitor (IC50: 0.019 μM). MAO-B-IN-6 is superior to Safinamide both in vitro and in vivo.

MAO-B ligand-1 is a selective MAO-B inhibitor.

MAO-B-IN-12 (Compound 16c) is a highly effective inhibitor of monoamine oxidase B (MAO-B), displaying significant potency with an IC50 value of 1.3 μM. Additionally, MAO-B-IN-12 exhibits notable neuroprotective activity [1].

MAO-IN-1 is a potent monoamine oxidase B (MAO B) inhibitor (IC50: 20 nM) for the study of neurologically related diseases.

MAO-B-IN-8 is a highly potent and reversible inhibitor of monoamine oxidase-B (MAO-B), which also exhibits inhibitory effects on the microglial production of neuroinflammatory mediators. This compound is specifically designed for use in research related to neurodegenerative diseases [1].

MAO-IN-M30 dihydrochloride (M 30 dihydrochloride) is a potent and brain selective monoamine oxidase (MAO) inhibitor (EC50 values are 37 and 57 nM for MAO-A and MAO-B, respectively). Also an iron chelator with antioxidant properties. Protects cells against 6-OHDA induced apoptosis. Attenuates MPTP depletion of DA and increases striatal monoamine levels in a mouse Parkinson's disease model.

hMAO-B-IN-5 is a potent reversible and selective human monoamine oxidase hMAO-B inhibitor (IC50:0.12μM). hMAO-B-IN-5 can cross the blood-brain barrier and can be used in the study of Parkinson's disease. It is a promising compound in the treatment and diagnosis of central nervous system diseases.

Peptide5 acetate reduces animal swelling, astrogliosis, and neuronal cell death after spinal cord injury. Peptide5 acetate significantly reduces the degree of spinal cord injury (SCI) in a rodent ex vivo model.